{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:09:48Z","timestamp":1784030988376,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00347-026-02394-z","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:55:42Z","timestamp":1770814542000},"page":"69-84","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapie der Fr\u00fchgeborenenretinopathie (ROP)","Treatment of retinopathy of prematurity (ROP)"],"prefix":"10.1007","volume":"123","author":[{"name":"Deutsche Ophthalmologische Gesellschaft e. V. (DOG)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim U.","family":"Krohne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Bertram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Plein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Eglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Feltgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Gehrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf A.","family":"Lagr\u00e8ze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Ostrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Pielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Retinologische Gesellschaft e.\u202fV. (RG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Berufsverband der Augen\u00e4rztinnen und Augen\u00e4rzte Deutschlands e.\u202fV. (BVA)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"2","key":"2394_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00347-011-2519-2","volume":"109","author":"Gesellschaft DO","year":"2012","unstructured":"Gesellschaft DO, Gesellschaft R, Deutschlands B der A (2012) Stellungnahme zum Einsatz von Bevacizumab in der Therapie der Fr\u00fchgeborenenretinopathie. Ophthalmologie 109(2):197\u2013204. https:\/\/doi.org\/10.1007\/s00347-011-2519-2","journal-title":"Ophthalmologe"},{"issue":"9","key":"2394_CR2","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00347-020-01170-x","volume":"117","author":"Deutsche Ophthalmologische Gesellschaft e.\u202fV. (DOG)","year":"2020","unstructured":"Deutsche Ophthalmologische Gesellschaft e.\u202fV. (DOG), Retinologische Gesellschaft e.\u202fV. (RG), Berufsverband der Augen\u00e4rzte Deutschlands e.\u202fV. (BVA) (2020) Statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of German Ophthalmologists on anti-VEGF therapy of retinopathy of prematurity : Released: 18\u00a0May 2020. Ophthalmologe 117(9):873\u2013885","journal-title":"Ophthalmologe"},{"issue":"Suppl\u00a02","key":"2394_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00347-021-01353-0","volume":"118","author":"RF Maier","year":"2021","unstructured":"Maier\u00a0RF, Hummler\u00a0H, Kellner\u00a0U, Krohne\u00a0TU, Lawrenz\u00a0B, Lorenz\u00a0B et\u00a0al (2021) Guidelines for ophthalmological screening of premature infants in Germany (S2k level, AWMF guidelines register no. 024\/010, March 2020) : Joint recommendation of the German Ophthalmological Society (DOG), Retinological Society (RG), Professional Association of Ophthalmologists in Germany e.\u202fV. (BVA), German Society of Paediatrics and Adolescent Medicine (DGKJ), Professional Association of Pediatricians (BVKJ), Federal Association \u201eThe Premature Child\u201c , Society for Neonatology and Paediatric Intensive Care Medicine (GNPI). Ophthalmologe 118(Suppl\u00a02):117\u2013131","journal-title":"Ophthalmologe"},{"key":"2394_CR4","unstructured":"AWMF Leitlinienregister: S3-Leitlinie Fr\u00fchgeborenen-Nachsorge im Kindes- und Jugendalter [Internet]. [cited 2025 Mar 4]. Available from: https:\/\/register.awmf.org\/de\/leitlinien\/detail\/071-013"},{"key":"2394_CR5","unstructured":"DOG, RG, BVA (2007) Empfehlung f\u00fcr die Durchf\u00fchrung von intravitrealen Injektionen (IVI). http:\/\/www.dog.org\/wp-content\/uploads\/2009\/09\/DOG_Empfehlung_Intravitreale_Injektionen.pdf. Accessed 17.7.2011"},{"key":"2394_CR6","doi-asserted-by":"crossref","unstructured":"(2013) Endophthalmitis prophylaxis in intravitreal operative medication management administration(IVOM). Ophthalmologe 110(10):1008\u20131012","DOI":"10.1007\/s00347-013-2946-3"},{"issue":"1","key":"2394_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1136\/archdischild-2024-327133","volume":"110","author":"TU Krohne","year":"2024","unstructured":"Krohne\u00a0TU, Camp\u00a0AT, Pfeil\u00a0JM, M\u00fcller\u00a0A, Stahl\u00a0A, Lagr\u00e8ze\u00a0WA et\u00a0al (2024) Retinopathy of prematurity in Germany over 13 years: incidences, treatment preferences and effects of national guideline changes. Arch Dis Child Fetal Neonatal Ed 110(1):37\u201342","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"3","key":"2394_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","volume":"256","author":"CY Huang","year":"2018","unstructured":"Huang\u00a0CY, Lien\u00a0R, Wang\u00a0NK, Chao\u00a0AN, Chen\u00a0KJ, Chen\u00a0TL et\u00a0al (2018) Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 256(3):479\u2013487","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"2394_CR9","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1167\/iovs.14-15842","volume":"56","author":"L Kong","year":"2015","unstructured":"Kong\u00a0L, Bhatt\u00a0AR, Demny\u00a0AB, Coats\u00a0DK, Li\u00a0A, Rahman\u00a0EZ et\u00a0al (2015) Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF\u20111 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci 56(2):956\u2013961","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"2394_CR10","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","volume":"98","author":"RL Avery","year":"2014","unstructured":"Avery\u00a0RL, Castellarin\u00a0AA, Steinle\u00a0NC, Dhoot\u00a0DS, Pieramici\u00a0DJ, See\u00a0R et\u00a0al (2014) Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 98(12):1636\u20131641","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"2394_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","volume":"172","author":"A Stahl","year":"2018","unstructured":"Stahl\u00a0A, Krohne\u00a0TU, Eter\u00a0N, Oberacher-Velten\u00a0I, Guthoff\u00a0R, Meltendorf\u00a0S et\u00a0al (2018) Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial. JAMA Pediatr 172(3):278\u2013286","journal-title":"JAMA Pediatr"},{"issue":"10208","key":"2394_CR12","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl\u00a0A, Lepore\u00a0D, Fielder\u00a0A, Fleck\u00a0B, Reynolds\u00a0JD, Chiang\u00a0MF et\u00a0al (2019) Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet 394(10208):1551\u20131559","journal-title":"Lancet"},{"key":"2394_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2024.113913","volume":"273","author":"CC Lee","year":"2024","unstructured":"Lee\u00a0CC, Chiang\u00a0MC, Chu\u00a0SM, Wu\u00a0WC, Ho\u00a0MMC, Lien\u00a0R (2024) Clinical Risk Factors for Retinopathy of Prematurity Reactivation after Intravitreal Antivascular Endothelial Growth Factor Injection. J\u00a0Pediatr 273:113913","journal-title":"J Pediatr"},{"issue":"10","key":"2394_CR14","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","volume":"128","author":"MF Chiang","year":"2021","unstructured":"Chiang\u00a0MF, Quinn\u00a0GE, Fielder\u00a0AR, Ostmo\u00a0SR, Chan\u00a0P, Berrocal\u00a0A et\u00a0al (2021) International Classification of Retinopathy of Prematurity, Third Edition. Ophthalmology 128(10):e51\u201368","journal-title":"Ophthalmology"},{"issue":"7","key":"2394_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner\u00a0HA, Kennedy\u00a0KA, Chuang\u00a0AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364(7):603\u2013615","journal-title":"N Engl J Med"},{"issue":"11","key":"2394_CR16","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck\u00a0MM, Chuang\u00a0AZ, Clark\u00a0WL, Hunt\u00a0MG, Norman\u00a0AA, Packwood\u00a0EA et\u00a0al (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 132(11):1327\u20131333","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"2394_CR17","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00347-012-2618-8","volume":"109","author":"TU Krohne","year":"2012","unstructured":"Krohne\u00a0TU, Aisenbrey\u00a0S, Holz\u00a0FG (2012) Current therapeutic options in retinopathy of prematurity. Ophthalmologe 109(12):1189\u20131197","journal-title":"Ophthalmologe"},{"issue":"1","key":"2394_CR18","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1111\/aos.14852","volume":"100","author":"A Stahl","year":"2022","unstructured":"Stahl\u00a0A, Br\u00fcnder\u00a0MC, Lagr\u00e8ze\u00a0WA, Moln\u00e1r\u00a0FE, Barth\u00a0T, Eter\u00a0N et\u00a0al (2022) Ranibizumab in retinopathy of prematurity - one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study. Acta Ophthalmol 100(1):e91\u2013e99","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"2394_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2025-002303","volume":"10","author":"A Stahl","year":"2025","unstructured":"Stahl\u00a0A, Br\u00fcnder\u00a0MC, Lagr\u00e8ze\u00a0WA, Moln\u00e1r\u00a0FE, Barth\u00a0T, Eter\u00a0N et\u00a0al (2025) Different ranibizumab dosages for retinopathy of prematurity: 5\u2011year follow-up data of the randomised, controlled CARE-ROP Study. BMJ Open Ophthalmol 10(1):e002303","journal-title":"BMJ Open Ophthalmol"},{"issue":"7","key":"2394_CR20","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.oret.2022.02.006","volume":"6","author":"BW Fleck","year":"2022","unstructured":"Fleck\u00a0BW, Reynolds\u00a0JD, Zhu\u00a0Q, Lepore\u00a0D, Marlow\u00a0N, Stahl\u00a0A et\u00a0al (2022) Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial. Ophthalmol Retina 6(7):628\u2013637","journal-title":"Ophthalmol Retina"},{"issue":"8","key":"2394_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1167\/tvst.9.8.43","volume":"9","author":"M Fidler","year":"2020","unstructured":"Fidler\u00a0M, Fleck\u00a0BW, Stahl\u00a0A, Marlow\u00a0N, Chastain\u00a0JE, Li\u00a0J et\u00a0al (2020) Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial. Transl Vis Sci Technol 9(8):43\u201343","journal-title":"Transl Vis Sci Technol"},{"issue":"10","key":"2394_CR22","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S2352-4642(21)00195-4","volume":"5","author":"N Marlow","year":"2021","unstructured":"Marlow\u00a0N, Stahl\u00a0A, Lepore\u00a0D, Fielder\u00a0A, Reynolds\u00a0JD, Zhu\u00a0Q et\u00a0al (2021) 2\u2011year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial. Lancet Child Adolesc Health 5(10):698\u2013707","journal-title":"Lancet Child Adolesc Health"},{"key":"2394_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102567","volume":"71","author":"N Marlow","year":"2024","unstructured":"Marlow\u00a0N, Reynolds\u00a0JD, Lepore\u00a0D, Fielder\u00a0AR, Stahl\u00a0A, Hao\u00a0H et\u00a0al (2024) Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trial. EClinicalMedicine 71:102567","journal-title":"EClinicalMedicine"},{"issue":"4","key":"2394_CR24","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1001\/jama.2022.10564","volume":"328","author":"A Stahl","year":"2022","unstructured":"Stahl\u00a0A, Sukgen\u00a0EA, Wu\u00a0WC, Lepore\u00a0D, Nakanishi\u00a0H, Mazela\u00a0J et\u00a0al (2022) Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial. JAMA 328(4):348\u2013359","journal-title":"JAMA"},{"issue":"12","key":"2394_CR25","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative G","year":"2003","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative G (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121(12):1684\u20131694","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"2394_CR26","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/s41433-023-02919-9","volume":"38","author":"A Stahl","year":"2024","unstructured":"Stahl\u00a0A, Azuma\u00a0N, Wu\u00a0WC, Lepore\u00a0D, Sukgen\u00a0E, Nakanishi\u00a0H et\u00a0al (2024) Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study. Eye (Lond) 38(8):1444\u20131453","journal-title":"Eye (Lond)"},{"issue":"8","key":"2394_CR27","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41433-024-02948-y","volume":"38","author":"A Stahl","year":"2024","unstructured":"Stahl\u00a0A, Azuma\u00a0N, Wu\u00a0WC, Lepore\u00a0D, Sukgen\u00a0E, Nakanishi\u00a0H et\u00a0al (2024) Correction: Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study. Eye (Lond) 38(8):1599\u20131600","journal-title":"Eye (Lond)"},{"issue":"4","key":"2394_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.8383","volume":"7","author":"A Stahl","year":"2024","unstructured":"Stahl\u00a0A, Nakanishi\u00a0H, Lepore\u00a0D, Wu\u00a0WC, Azuma\u00a0N, Jacas\u00a0C et\u00a0al (2024) Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity: Two-Year Efficacy and Safety Outcomes in the Nonrandomized Controlled Trial FIREFLEYE next. JAMA Netw Open 7(4):e248383","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2394_CR29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00347-018-0675-3","volume":"115","author":"PP Larsen","year":"2018","unstructured":"Larsen\u00a0PP, Br\u00fcnder\u00a0MC, Petrak\u00a0M, Jehle\u00a0V, Lagr\u00e8ze\u00a0WA, Holz\u00a0FG et\u00a0al (2018) Screening for retinopathy of prematurity: Trends over the past 5 years in two German university hospitals. Ophthalmologe 115(6):469\u2013475","journal-title":"Ophthalmologe"},{"issue":"6","key":"2394_CR30","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s00347-018-0701-5","volume":"115","author":"JM Walz","year":"2018","unstructured":"Walz\u00a0JM, Bemme\u00a0S, Reichl\u00a0S, Akman\u00a0S, Breu\u00df\u00a0H, S\u00fcsskind\u00a0D et\u00a0al (2018) Treated cases of retinopathy of prematurity in Germany : 5\u2011year data from the Retina.net ROP registry. Ophthalmologe 115(6):476\u2013488","journal-title":"Ophthalmologe"},{"issue":"3","key":"2394_CR31","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1111\/aos.15753","volume":"102","author":"K Winter","year":"2024","unstructured":"Winter\u00a0K, Pfeil\u00a0JM, Engmann\u00a0H, Aisenbrey\u00a0S, Lorenz\u00a0B, Hufendiek\u00a0K et\u00a0al (2024) Comparability of input parameters in the German Retina.net ROP registry and the EU-ROP registry - An exemplary comparison between 2011 and 2021. Acta Ophthalmol 102(3):e314\u2013e321","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"2394_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3928\/23258160-20220211-01","volume":"53","author":"H SE","year":"2022","unstructured":"SE\u00a0H, K\u00a0S, EF\u00a0A, A\u00a0G, AM\u00a0B, TG\u00a0M (2022) Sequential Short Interval Anti-VEGF for the Treatment of Stage 4 Retinopathy of Prematurity. Ophthalmic Surg Lasers Imaging Retina 53(3):159\u2013163","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"1","key":"2394_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3928\/01913913-20191030-01","volume":"57","author":"P Chandra","year":"2020","unstructured":"Chandra\u00a0P, Kumawat\u00a0D, Agarwal\u00a0D, Chawla\u00a0R (2020) Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation. J\u00a0Pediatr Ophthalmol Strabismus 57(1):61\u201366","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"2394_CR34","unstructured":"Gesellschaft f\u00fcr Neonatologie und p\u00e4diatrische Intensivmedizin (GNPI), Deutsche Ophthalmologische Gesellschaft (DOG), Retinologische Gesellschaft (RG) (2024) Informationsbogen zur Aufkl\u00e4rung bei behandlungsbed\u00fcrftiger Fr\u00fchgeborenenretinopathie. https:\/\/dog.org\/fuer-aerzte\/leitlinien-stellungnahmen-empfehlungen\/diabetes-glaskoerper-netzhaut\/stellungnahmen-diabetes-glaskoerper-netzhaut\/informationsbogen-zur-aufklaerung-bei-behandlungsbeduerftiger-fruehgeborenenretinopathie"},{"key":"2394_CR35","doi-asserted-by":"crossref","unstructured":"Wallace DK, Kraker RT, Freedman SF, Crouch ER, Bhatt AR, Hartnett ME, et\u00a0al. Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity. JAMA Ophthalmol. 2020 Apr 23;","DOI":"10.1001\/jamaophthalmol.2020.0334"},{"issue":"1","key":"2394_CR36","doi-asserted-by":"publisher","first-page":"10.e1","DOI":"10.1016\/j.jaapos.2022.11.020","volume":"27","author":"DK Wallace","year":"2023","unstructured":"Wallace\u00a0DK, Hercinovic\u00a0A, Freedman\u00a0SF, Crouch\u00a0ER, Bhatt\u00a0AR, Hartnett\u00a0ME et\u00a0al (2023) Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity. J\u00a0AAPOS 27(1):10.e1\u201310.e8","journal-title":"J AAPOS"},{"issue":"3","key":"2394_CR37","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/j.jcrs.0000000000000754","volume":"48","author":"P Kanclerz","year":"2022","unstructured":"Kanclerz\u00a0P, Myers\u00a0WG (2022) Chlorhexidine and other alternatives for povidone-iodine in ophthalmic surgery: review of comparative studies. J\u00a0Cataract Refract Surg 48(3):363\u2013369","journal-title":"J Cataract Refract Surg"},{"issue":"1","key":"2394_CR38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.oret.2023.08.007","volume":"8","author":"AV Mishra","year":"2024","unstructured":"Mishra\u00a0AV, Tong\u00a0CM, Faes\u00a0L, Cheema\u00a0MK, Plemel\u00a0D, Rubin\u00a0U et\u00a0al (2024) Comparison of Endophthalmitis Rates after Alcohol-Based Chlorhexidine and Povidone-Iodine Antisepsis for Intravitreal Injections. Ophthalmol Retina 8(1):18\u201324","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"2394_CR39","doi-asserted-by":"publisher","first-page":"F21","DOI":"10.1136\/archdischild-2013-303799","volume":"99","author":"J Aitken","year":"2014","unstructured":"Aitken\u00a0J, Williams\u00a0FLR (2014) A\u00a0systematic review of thyroid dysfunction in preterm neonates exposed to topical iodine. Arch Dis Child Fetal Neonatal Ed 99(1):F21\u2013F28","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"10","key":"2394_CR40","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00103-007-0337-0","volume":"50","author":"Committee of Hospital Hygiene and Infection Prevention of the Robert Koch Institute","year":"2007","unstructured":"Committee of Hospital Hygiene and Infection Prevention of the Robert Koch Institute (2007) Recommendation for the prevention of nosocomial infections in neonatal intensive care patients with a\u00a0birth weight less than 1,500\u202fg. Report by the Committee of Hospital Hygiene and Infection Prevention of the Robert Koch Institute. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 50(10):1265\u20131303","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"6","key":"2394_CR41","doi-asserted-by":"publisher","first-page":"e494","DOI":"10.1111\/aos.12347","volume":"92","author":"T Ristau","year":"2014","unstructured":"Ristau\u00a0T, Kirchhof\u00a0B, Fauser\u00a0S (2014) Antisepsis with polyhexanide is effective against endophthalmitis after intravitreal injections. Acta Ophthalmol 92(6):e494\u2013496","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"2394_CR42","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00347-004-1120-3","volume":"102","author":"F Hansmann","year":"2005","unstructured":"Hansmann\u00a0F, Kramer\u00a0A, Ohgke\u00a0H, Strobel\u00a0H, Muller\u00a0M, Geerling\u00a0G (2005) Lavasept as an alternative to PVP-iodine as a\u00a0preoperative antiseptic in ophthalmic surgery. Randomized, controlled, prospective double-blind trial. Ophthalmologe 102(11):1043\u20131050","journal-title":"Ophthalmologe"},{"issue":"2","key":"2394_CR43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/00006982-199703000-00009","volume":"17","author":"RJ Hairston","year":"1997","unstructured":"Hairston\u00a0RJ, Maguire\u00a0AM, Vitale\u00a0S, Green\u00a0WR (1997) Morphometric analysis of pars plana development in humans. Retina 17(2):135\u2013138","journal-title":"Retina"},{"issue":"8","key":"2394_CR44","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1136\/bjo.2009.162156","volume":"94","author":"CK Patel","year":"2010","unstructured":"Patel\u00a0CK, Walker\u00a0NJ, Kam\u00a0JK (2010) A\u00a0new, theoretically safer method of intravitreal injection of bevacizumab in progressive retinopathy of prematurity using scleral trans-illumination. Br J Ophthalmol 94(8):1107\u20131109","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"2394_CR45","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0161-6420(00)00527-3","volume":"108","author":"GE Quinn","year":"2001","unstructured":"Quinn\u00a0GE, Dobson\u00a0V, Siatkowski\u00a0R, Hardy\u00a0RJ, Kivlin\u00a0J, Palmer\u00a0EA et\u00a0al (2001) Does cryotherapy affect refractive error? Results from treated versus control eyes in the cryotherapy for retinopathy of prematurity trial. Ophthalmology 108(2):343\u2013347","journal-title":"Ophthalmology"},{"issue":"2","key":"2394_CR46","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0161-6420(99)00042-1","volume":"107","author":"MJ Banach","year":"2000","unstructured":"Banach\u00a0MJ, Ferrone\u00a0PJ, Trese\u00a0MT (2000) A comparison of dense versus less dense diode laser photocoagulation patterns for threshold retinopathy of prematurity. Ophthalmology 107(2):324\u2013327","journal-title":"Ophthalmology"},{"issue":"8","key":"2394_CR47","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu\u00a0J, Blair\u00a0MP, Shapiro\u00a0MJ, Lichtenstein\u00a0SJ, Galasso\u00a0JM, Kapur\u00a0R (2012) Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 130(8):1000\u20131006","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"2394_CR48","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner\u00a0HA, Geloneck\u00a0MM, Chuang\u00a0AZ (2016) Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy. Ophthalmology 123(9):1845\u20131855","journal-title":"Ophthalmology"},{"key":"2394_CR49","unstructured":"Andrassi-Darida M, Mais C, Stieger K, Lorenz B. [Fluorescence Angiography-assisted Management of Recurrences in Aggressive Posterior Retinopathy of Prematurity (APROP) after Intravitreal Monotherapy with 0.312\u202fmg Bevacizumab]. Klin Monbl Augenheilkd. 2019 Nov 26;"},{"issue":"5","key":"2394_CR50","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ophtha.2018.12.034","volume":"126","author":"AR Fielder","year":"2019","unstructured":"Fielder\u00a0AR, Wallace\u00a0DK, Stahl\u00a0A, Reynolds\u00a0JD, Chiang\u00a0MF, Quinn\u00a0GE (2019) Describing Retinopathy of Prematurity: Current Limitations and New Challenges. Ophthalmology 126(5):652\u2013654","journal-title":"Ophthalmology"},{"issue":"1","key":"2394_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148019","volume":"11","author":"R Lien","year":"2016","unstructured":"Lien\u00a0R, Yu\u00a0MH, Hsu\u00a0KH, Liao\u00a0PJ, Chen\u00a0YP, Lai\u00a0CC et\u00a0al (2016) Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment. PLoS ONE 11(1):e0148019","journal-title":"PLoS ONE"},{"key":"2394_CR52","doi-asserted-by":"crossref","unstructured":"Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN, et\u00a0al. Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity. Pediatrics. 2016 Apr;137(4).","DOI":"10.1542\/peds.2015-3218"},{"issue":"3","key":"2394_CR53","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0161-6420(92)31968-2","volume":"99","author":"GE Quinn","year":"1992","unstructured":"Quinn\u00a0GE, Dobson\u00a0V, Repka\u00a0MX, Reynolds\u00a0J, Kivlin\u00a0J, Davis\u00a0B, The Cryotherapy for Retinopathy of Prematurity Cooperative Group et\u00a0al (1992) Development of myopia in infants with birth weights less than 1251 grams. Ophthalmology 99(3):329\u2013340","journal-title":"Ophthalmology"},{"issue":"2","key":"2394_CR54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jaapos.2004.12.018","volume":"9","author":"E Garcia-Valenzuela","year":"2005","unstructured":"Garcia-Valenzuela\u00a0E, Kaufman\u00a0LM (2005) High myopia associated with retinopathy of prematurity is primarily lenticular. J\u00a0AAPOS 9(2):121\u2013128","journal-title":"J AAPOS"},{"key":"2394_CR55","unstructured":"https:\/\/dog.org\/wp-content\/uploads\/sites\/11\/2009\/09\/ROP-Pass_Version-3_4_FORMULAR4.pdf"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02394-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-026-02394-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02394-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:02:24Z","timestamp":1784030544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-026-02394-z"}},"subtitle":["S1-Leitlinie von Deutsche Ophthalmologische Gesellschaft (DOG), Retinologische Gesellschaft (RG), Berufsverband der Augen\u00e4rztinnen und Augen\u00e4rzte Deutschlands (BVA), Bundesverband \u201eDas fr\u00fchgeborene Kind\u201c, Deutscher Blinden- und Sehbehindertenverband (DBSV), PRO RETINA Deutschland","S1\u00a0guidelines of the German Society of Ophthalmology (DOG), the German Retina Society (RG), the German Professional Association of Ophthalmologists (BVA), the Federal Association \u201cThe Premature Infant\u201d, the German Federation of the Blind and Partially Sighted (DBSV), PRO RETINA Germany"],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":55,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2394"],"URL":"https:\/\/doi.org\/10.1007\/s00347-026-02394-z","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Siehe Tab.\u00a0\n                      \n                      im Anhang.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}